SCHEMBL4801364

SCHEMBL4801364

COC(=O)c1ccc(CO/N=C/c2cn(Cc3ccccc3)c3ccccc23)cc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
KMT2A Q03164 6/20 0.50
MEN1 O00255 5/20 0.50
POLB P06746 4/20 0.50
CASP6 P55212 1/20 0.50
RCE1 Q9Y256 1/20 0.50
GAA P10253 4/20 0.49
SENP7 Q9BQF6 2/20 0.48
APP P05067 1/20 0.47
SNCA P37840 1/20 0.47
ALDH1A1 P00352 6/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
THRB P10828 1/20 0.47
BACE1 P56817 1/20 0.46
GCGR P47871 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HTT P42858 1/20 0.45
KDM4E B2RXH2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4801382 1.00 MAPT (0.50) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4797184 0.92 KMT2A (0.50) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4797195 0.92 KMT2A (0.50) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4799000 0.79 MAPT (0.52) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4800513 0.79 MAPT (0.52) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4798983 0.79 MAPT (0.52) MAPTKMT2AMEN1POLBCASP6
SCHEMBL2430574 0.73 NR4A2 (0.72) MAPTKMT2AMEN1GAAALDH1A1
SCHEMBL4800748 0.72 ALDH1A1 (0.50) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4800762 0.72 ALDH1A1 (0.50) MAPTKMT2AMEN1POLBCASP6
SCHEMBL4798224 0.71 ALDH1A1 (0.54) MAPTKMT2AMEN1POLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342039-B2 Substituted indole oximes WYETH (US) 2008-03-11 US disclosed
US-20050119326-A1 Substituted aryloximes WYETH (US) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119326-A1 Substituted aryloximes IDO2, TDO2, IDO1 MAPT 4402/4885KMT2A 382/4885MEN1 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.